Last updated: February 27, 2026
Overview of NDC 00409-3977
NDC 00409-3977 corresponds to Bremelanotide, marketed as Vyleesi. Approved by the FDA in June 2019, Vyleesi is indicated for enhancing sexual desire in premenopausal women with hypoactive sexual desire disorder (HSDD). Its unique mechanism involves melanocortin receptor agonism, positioning it as a non-hormonal alternative.
Market Context
Patient Population
- Estimated U.S. premenopausal women with HSDD: approximately 10 million.
- Eligible patients (diagnosed and prescribed): projected 20-25% of the total population, reflecting early adoption and access barriers.
Competitive Landscape
- Direct competition: Addyi (flibanserin)
- Indirect competition: off-label use of other medications and non-pharmaceutical interventions
- Addyi's sales peaked at $45 million in 2020, with a gradual decline due to side effects and usage limitations.
Adoption Factors
- Physician prescribing behavior
- Insurance coverage
- Patient acceptance and awareness
Pricing Data
Wholesale Acquisition Cost (WAC) and Average Wholesale Price (AWP)
| Parameter |
2023 Data |
Notes |
| WAC |
approximately $1,200 per month |
Estimated based on similar drugs' data |
| AWP |
approximately $2,000 per month |
Usually higher than WAC due to markups |
Insurance and Reimbursement Landscape
- Medicare and Medicaid: limited coverage initially, with potential expansion.
- Commercial insurers: negotiations on formulary placement influence patient access.
- Out-of-pocket costs: estimated at $400-$800 monthly, depending on coverage.
Price Trends
- Initial launch prices typically set at WAC or slightly above.
- Competitive pressure from Addyi influences pricing strategies.
- Potential discounts, patient assistance programs, or copay cards could lower effective patient costs.
Market Size and Revenue Projections
Short-Term (Next 1-2 Years)
- Estimated prescriptions: 50,000–100,000 annually in the U.S.
- Revenue forecast: $60–$150 million, assuming 20–25% market penetration among the target population.
- Factors influencing growth: insurance coverage, physician awareness campaigns, patient acceptance.
Mid to Long-Term (3-5 Years)
- Growing awareness and expanding insurance coverage could increase prescriptions by 150–200%.
- Potential for market expansion to other indications, such as male hypoactive sexual desire disorder (HSDD), pending clinical trials and regulatory approval.
- Estimated revenues: up to $300–$600 million, assuming sustained growth and market penetration.
Price Sensitivity and Competition
- Price reductions possible due to insurance negotiations or biosimilar entries (if biosimilars develop).
- Addyi and emerging therapies may influence patient and provider preferences, affecting pricing strategies.
Regulatory and Policy Impact
- Health policy changes regarding sexual health drugs could impact formulary access.
- Medicaid and Medicare formulary decisions will influence patient affordability and overall market size.
Risks and Opportunities
Risks:
- Limited market awareness initially.
- Insufficient insurance coverage could restrict adoption.
- Competitive responses, including price discounts or new therapies.
Opportunities:
- Rising recognition of HSDD as a treatable condition.
- Expansion into other sexual dysfunction indications.
- Development of needle-free or oral delivery systems.
Key Takeaways
- NDC 00409-3977 (Vyleesi) entered a niche market with a sizable potential patient population.
- Pricing strategies will likely balance WAC/AWP levels with insurance negotiations and patient assistance.
- Revenues could reach hundreds of millions annually within 3-5 years, depending on market adoption.
- The competitive landscape remains moderate with Addyi as the primary existing therapy.
- Policy shifts and clinical developments will shape future market size and pricing.
FAQs
Q1: What is the main factor determining the drug's market penetration?
A: Insurance coverage and physician prescription practices significantly influence adoption.
Q2: How does the pricing of Vyleesi compare to Addyi?
A: Vyleesi's estimated monthly cost is around $1,200-$2,000, comparable to Addyi but with different dosing and side effect profiles.
Q3: What potential regulatory changes could impact the market?
A: Expanded insurance coverage policies and approval for additional indications could increase market size.
Q4: Are biosimilars of Vyleesi likely?
A: Biosimilar development is unlikely because Vyleesi is a peptide, not a biologic; however, synthetic analogs could emerge.
Q5: What strategies could expand the drug’s market?
A: Improving awareness campaigns, expanding insurance coverage, and pursuing new indications.
References
[1] U.S. Food and Drug Administration. (2019). FDA approves Vyleesi for premenopausal women with hypoactive sexual desire disorder.
[2] IQVIA. (2023). U.S. prescription drug market data.
[3] Medicare.gov. (2023). Coverage policies for sexual health drugs.
[4] Drug Price Competition and Patent Term Restoration Act. (1984).
[5] Deloitte. (2022). Pharmaceutical pricing strategies and market dynamics.
